YANGZHOU, China, July 1, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ('MHUA' or the 'Company') (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced today that its board of directors (the 'Board') has approved and authorized a share repurchase program of up to $3 million of the Company's outstanding ordinary shares (the 'Share Repurchase Program').

中国扬州，2024年7月1日/新华社/--梅花国际医疗技术有限公司（“MHUA”或“公司”）（纳斯达克：MHUA），一家声誉良好的I、II和III类一次性医疗器械制造商和供应商，在中国设有运营子公司，今天宣布其董事会（“董事会”）批准并授权了一项高达300万美元的公司已发行普通股的股份回购计划（“股份回购计划”）。

The Company intends to cancel all shares repurchased pursuant to this Share Repurchase Program..

公司打算取消根据本股份回购计划回购的所有股份。。

The ordinary shares may be repurchased from time to time through open market purchases or privately negotiated transactions at prevailing prices, in accordance with securities laws and other legal requirements, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company's insider trading policy, and subject to market conditions and other factors..

根据证券法和其他法律要求，包括经修订的《1934年证券交易法》第10b-18条和第10b5-1条规则以及公司的内幕交易政策，可以通过公开市场购买或以现行价格私下协商交易的方式不时回购普通股，并受市场条件和其他因素的影响。。

'With ongoing efforts to innovate, expand our premium product offerings, and enhance operational efficiency through optimized production processes and the application of AI, we continue to strengthen our business model and generate significant cash flow, which enables us to invest for the long term,' said Xin 'Steven' Wang, Chief Executive Officer of Meihua.

梅花首席执行官王欣（Xin‘Steven’Wang）表示，通过不断努力创新，扩大优质产品供应，并通过优化生产流程和人工智能的应用提高运营效率，我们将继续加强业务模式，产生可观的现金流，这使我们能够进行长期投资。

'This Share Repurchase Program including the planned cancellation of repurchased shares not only underscores our confidence in Meihua's future growth but also demonstrates our commitment to enhancing shareholder value through concrete actions.'.

“此次股份回购计划（包括计划取消回购股份）不仅突显了我们对梅花未来增长的信心，也表明了我们致力于通过具体行动提高股东价值。”。

The adoption of this Share Repurchase Program does not obligate the Company to acquire any specific amount of ordinary shares, and it may be suspended or discontinued at any time by the Board.

本股份回购计划的采用并不意味着本公司有义务收购任何特定数量的普通股，董事会可随时暂停或终止该计划。

The Company expects to implement the Share Repurchase Program and a corresponding 10b5-1 plan following the filing of its Semi-Annual Report on Form 6-K for the period ending June 30, 2024.

公司预计在提交截至2024年6月30日的6-K表半年度报告后，将实施股份回购计划和相应的10b5-1计划。

About Meihua International Medical Technologies Co., Ltd.

关于梅花国际医疗科技有限公司。

Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua's own brands and are also sourced and distributed from other manufacturers.

梅花国际医疗科技有限公司是一家信誉良好的一次性医疗器械制造商和供应商，在中国设有运营子公司。该公司生产和销售一类一次性医疗器械，如用于片剂的HDPE瓶和用于滴眼液、咽喉带和肛门袋的LDPE瓶，以及二类和三类一次性医疗器械，如一次性识别手镯、妇科检查包、检查包、手术包、医疗刷、医用敷料、医用导管、子宫组织吸引台、病毒采样管、一次性输液泵、电子泵和麻醉穿刺包，以及其他以梅花自有品牌销售的产品，也从其他制造商那里采购和分销。

The Company has received an international 'CE' certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania..

该公司已获得国际“CE”认证和ISO 13485体系认证，并已在FDA（注册号：3006554788）注册了20多种I类产品。公司为医院、药店、医疗机构和医疗设备公司服务了30多年，为国内销售提供了1000多种产品，120多种产品出口到欧洲、北美、南美、亚洲、非洲和大洋洲的30多个国家。。

For more information, please visit www.meihuamed.com.

有关更多信息，请访问www.meihuamed.com。

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts.

本新闻稿包含1995年《私人证券诉讼改革法案》定义的前瞻性声明。。

When the Company uses words such as 'may,' 'will,' 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements.

当公司使用诸如“可能”、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“项目”、“估计”或类似的表达方式时，这些表达方式不仅仅与历史问题有关，而是在做出前瞻性陈述。前瞻性陈述并非对未来业绩的保证，涉及的风险和不确定性可能导致实际结果与前瞻性陈述中讨论的公司预期存在重大差异。

These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company's future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S.

这些声明具有不确定性和风险，包括但不限于以下方面：公司实现目标和战略的能力，全面执行计划协议的能力，公司未来的业务发展和未来业务发展计划，包括成功开发机器人辅助手术系统并获得此类系统的许可和认证的能力，财务状况和运营结果，产品和服务需求和接受程度，声誉和品牌，竞争和定价的影响，技术变化，政府法规，中国总体经济和商业状况的波动，以及公司向美国提交的报告中包含的任何上述或与之相关的假设和其他风险。

Securities and Exchange Commission ('SEC'). For these reasons, among others, investors are cautioned not to place undue reliance upon a.

美国证券交易委员会（“SEC”）。除其他原因外，投资者应注意不要过度依赖a。

For investor and media inquiries, please contact:

投资者和媒体咨询，请联系：

IR Department

IR部门

Email: secretary@meihuamed.com

电子邮件：secretary@meihuamed.com

Tel: +86-0514-89800199

电话：+86-0514-89800199

Christensen

克里斯滕森

Yang Song

Email: yang.song@christensencomms.com

电子邮件yang.song@christensencomms.com

Tel: +86-010-59001548

View original content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-co-ltd-announces-share-repurchase-program-of-up-to-3-million-302186765.html

查看原始内容：https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-co-ltd-announces-share-repurchase-program-of-up-to-3-million-302186765.html

SOURCE Meihua International Medical Technologies Co., Ltd.

来源梅花国际医疗科技有限公司。

Company Codes: NASDAQ-NMS:MHUA

公司代码：NASDAQ-NMS：MHUA